Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS G12X||myelodysplastic syndrome||not applicable||N/A||Guideline||Prognostic||NRAS G12X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).||detail...|
|NRAS G12X||colorectal cancer||resistant||Cetuximab||FDA contraindicated||Actionable||Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).||detail...|
|NRAS G12X||colorectal cancer||resistant||Panitumumab||FDA contraindicated||Actionable||Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).||detail...|
|NRAS G12X||Advanced Solid Tumor||no benefit||MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor||Binimetinib||Phase II||Actionable||In a Phase II trial (MATCH), Mektovi (binimetinib) treatment resulted in an objective response rate of 2.1% (1/47) that was deemed nonpromising in patients with advanced solid tumors harboring NRAS mutations at codon 12 (n=17), 13 (n=8), or 61 (n=22), with a 6-month progression-free survival (PFS) of 29.2%, a median PFS of 3.5 months, and a median overall survival of 10.5 months (PMID: 33637626; NCT02465060).||33637626|